We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Prostate cancer: To screen, or not to screen? That is the question.
- Abstract
Prostate cancer screening using the PSA blood test is not recommended in major developed countries due to concerns of overdiagnosis and overtreatment. However, there has been renewed interest in screening, with recent studies providing further data on the topic. The CAP trial in the UK showed a small decrease in prostate cancer-specific mortality at 15 years but no effect on overall survival. The ProScreen trial in Finland found that screening resulted in additional high-grade and low-grade prostate cancer diagnoses. The PRAISE-U project, funded by the European Union, aims to evaluate the feasibility and effectiveness of organized prostate cancer screening using PSA testing and MRI scanning. The TRANSFORM study in the UK will further explore the utility of MRI scanning in early diagnosis. The Lancet Commission on Prostate Cancer predicts a significant increase in global prostate cancer cases, highlighting the need for early diagnosis and screening, particularly in low and middle-income countries. However, the challenge remains in identifying clinically significant prostate cancer. It may take several years to determine the impact of renewed interest in screening and advancements in technology.
- Subjects
PROSTATE cancer; EARLY detection of cancer; MEDICAL screening; PROSTATE-specific antigen
- Publication
BJU International, 2024, Vol 133, Issue 6, p635
- ISSN
1464-4096
- Publication type
Article
- DOI
10.1111/bju.16386